About Bausch + Lomb Corporation
https://www.bausch.comBausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical.
CEO
Brenton L. Saunders
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
RBC Capital
Outperform
Raymond James
Outperform
Evercore ISI Group
Outperform
Morgan Stanley
Overweight
Wells Fargo
Equal Weight
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
ICAHN CARL C
Shares:3.5M
Value:$60.62M
DEUTSCHE BANK AG\
Shares:3.5M
Value:$60.62M
OAKTREE CAPITAL MANAGEMENT LP
Shares:3.25M
Value:$56.21M
Summary
Showing Top 3 of 104
About Bausch + Lomb Corporation
https://www.bausch.comBausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.28B ▲ | $676M ▼ | $-28M ▲ | -2.19% ▲ | $-0.08 ▲ | $207M ▲ |
| Q2-2025 | $1.28B ▲ | $764M ▲ | $-62M ▲ | -4.85% ▲ | $-0.18 ▲ | $88M ▲ |
| Q1-2025 | $1.14B ▼ | $738M ▲ | $-212M ▼ | -18.65% ▼ | $-0.6 ▼ | $20M ▼ |
| Q4-2024 | $1.28B ▲ | $692M ▲ | $-3M ▼ | -0.23% ▼ | $-0.01 ▼ | $194M ▲ |
| Q3-2024 | $1.2B | $689M | $4M | 0.33% | $0.01 | $152M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $310M ▲ | $13.83B | $7.33B ▲ | $6.43B ▼ |
| Q2-2025 | $272M ▲ | $13.83B ▲ | $7.32B ▲ | $6.44B ▲ |
| Q1-2025 | $202M ▼ | $13.43B ▼ | $7B ▲ | $6.36B ▼ |
| Q4-2024 | $305M ▼ | $13.47B ▼ | $6.92B ▲ | $6.47B ▼ |
| Q3-2024 | $329M | $13.52B | $6.85B | $6.59B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-28M ▲ | $139.05M ▲ | $-61.3M ▲ | $-12.55M ▼ | $60M ▲ | $64.53M ▲ |
| Q2-2025 | $-58M ▲ | $35M ▲ | $-90M ▲ | $90M ▲ | $57M ▲ | $-54M ▲ |
| Q1-2025 | $-211M ▼ | $-25M ▼ | $-116M ▲ | $31M ▼ | $-101M ▼ | $-135M ▼ |
| Q4-2024 | $-2M ▼ | $22M ▼ | $-185M ▼ | $146M ▲ | $-34M ▼ | $-70M ▼ |
| Q3-2024 | $8M | $154M | $-96M | $-20M | $48M | $94M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Branded and Other Generic Products | $70.00M ▲ | $50.00M ▼ | $60.00M ▲ | $60.00M ▲ |
 Device Products | $480.00M ▲ | $450.00M ▼ | $470.00M ▲ | $480.00M ▲ |
 Other Revenues | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $0 ▼ |
 Over the Counter Products | $460.00M ▲ | $410.00M ▼ | $480.00M ▲ | $450.00M ▼ |
 Pharmaceutical Products | $270.00M ▲ | $220.00M ▼ | $260.00M ▲ | $280.00M ▲ |
Revenue by Geography
| Region | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
 CANADA | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ |
 CHINA | $80.00M ▲ | $90.00M ▲ | $90.00M ▲ | $100.00M ▲ |
 FRANCE | $60.00M ▲ | $60.00M ▲ | $50.00M ▼ | $50.00M ▲ |
 GERMANY | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $30.00M ▼ |
 ITALY | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
 JAPAN | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $50.00M ▲ |
 KOREA REPUBLIC OF | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
 MEXICO | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
 Other Countries | $170.00M ▲ | $170.00M ▲ | $170.00M ▲ | $240.00M ▲ |
 POLAND | $10.00M ▲ | $20.00M ▲ | $20.00M ▲ | $10.00M ▼ |
 SPAIN | $20.00M ▲ | $30.00M ▲ | $20.00M ▼ | $30.00M ▲ |
 United States and Puerto Rico | $540.00M ▲ | $610.00M ▲ | $610.00M ▲ | $660.00M ▲ |
CEO
Brenton L. Saunders
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
RBC Capital
Outperform
Raymond James
Outperform
Evercore ISI Group
Outperform
Morgan Stanley
Overweight
Wells Fargo
Equal Weight
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
ICAHN CARL C
Shares:3.5M
Value:$60.62M
DEUTSCHE BANK AG\
Shares:3.5M
Value:$60.62M
OAKTREE CAPITAL MANAGEMENT LP
Shares:3.25M
Value:$56.21M
Summary
Showing Top 3 of 104